MAIA Stock Forecast 2025-2026
Distance to MAIA Price Targets
MAIA Price Momentum
10 Quality Stocks Worth Considering Now
Researching MAIA (MAIA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MAIA and similar high-potential opportunities.
Latest MAIA Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, MAIA has a bullish consensus with a median price target of $12.14 (ranging from $10.27 to $14.00). Currently trading at $1.55, the median forecast implies a 682.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert LeBoyer at Noble Capital Markets, projecting a 803.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MAIA Analyst Ratings
MAIA Price Target Range
Latest MAIA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MAIA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | Robert LeBoyer | Outperform | Initiates | $14.00 |
Maia Biotechnology Inc. (MAIA) Competitors
The following stocks are similar to MAIA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Maia Biotechnology Inc. (MAIA) Financial Data
Maia Biotechnology Inc. has a market capitalization of $45.86M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -1,131.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Maia Biotechnology Inc. (MAIA) Business Model
About Maia Biotechnology Inc.
Develops therapies for cancer treatment.
Maia Biotechnology Inc. generates revenue by developing and commercializing innovative cancer therapies, particularly those that leverage the immune system. The company focuses on creating targeted treatments for significant oncology indications, which allows it to address unmet medical needs and potentially improve patient outcomes.
With a strong emphasis on research and development, Maia is positioned to lead in the biotechnology sector, especially in oncology, amidst the growing global challenge of cancer. The company's proprietary programs underscore its commitment to transforming cancer treatment and enhancing the quality of life for patients who have not responded to traditional therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Vlad Vitoc M.B.A., M.D.
Country
United States
IPO Year
2022
Website
maiabiotech.comMaia Biotechnology Inc. (MAIA) Latest News & Analysis
MAIA Biotechnology's CEO outlined expected clinical milestones for a new cancer immunotherapy in a 2025 letter to shareholders.
MAIA Biotechnology's CEO outlining clinical milestones signals potential advancements in cancer treatment, which could impact stock performance and investor confidence.
MAIA Biotechnology, Inc. (MAIA) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects.
MAIA Biotechnology's upgrade to Zacks Rank #2 signals strong potential for earnings growth, likely increasing investor confidence and driving stock prices higher.
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
25 days agoMAIA Biotechnology will present a poster at the European Lung Cancer Congress 2025, as announced in a recent press release.
MAIA Biotechnology’s presentation at a major cancer congress could indicate progress in its drug development pipeline, potentially influencing stock performance and investor sentiment.
MAIA Biotechnology has received USAN Council approval for the nonproprietary name "Ateganosine" for its anticancer agent, THIO.
USAN approval for Ateganosine boosts MAIA Biotechnology's credibility and market potential, indicating progress in cancer treatment that could attract investment and affect stock performance.
MAIA Biotechnology has published a peer-reviewed study highlighting the effectiveness and potential of its new THIO prodrug.
MAIA Biotechnology's peer-reviewed study on its THIO prodrug highlights its efficacy, potentially increasing investor confidence and interest in the company's growth prospects and stock value.
MAIA Biotechnology announced the expansion of its THIO-101 Phase 2 trial for non-small cell lung cancer, focusing on overall response rates in advanced NSCLC patients undergoing third-line therapy.
The expansion of MAIA's THIO-101 trial could enhance its market position in cancer treatment, potentially leading to increased revenue and stock value if results are favorable.
Frequently Asked Questions About MAIA Stock
What is Maia Biotechnology Inc.'s (MAIA) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Maia Biotechnology Inc. (MAIA) has a median price target of $12.14. The highest price target is $14.00 and the lowest is $10.27.
Is MAIA stock a good investment in 2025?
According to current analyst ratings, MAIA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MAIA stock?
Wall Street analysts predict MAIA stock could reach $12.14 in the next 12 months. This represents a 682.9% increase from the current price of $1.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Maia Biotechnology Inc.'s business model?
Maia Biotechnology Inc. generates revenue by developing and commercializing innovative cancer therapies, particularly those that leverage the immune system. The company focuses on creating targeted treatments for significant oncology indications, which allows it to address unmet medical needs and potentially improve patient outcomes.
What is the highest forecasted price for MAIA Maia Biotechnology Inc.?
The highest price target for MAIA is $14.00 from Robert LeBoyer at Noble Capital Markets, which represents a 803.2% increase from the current price of $1.55.
What is the lowest forecasted price for MAIA Maia Biotechnology Inc.?
The lowest price target for MAIA is $10.27 from at , which represents a 562.6% increase from the current price of $1.55.
What is the overall MAIA consensus from analysts for Maia Biotechnology Inc.?
The overall analyst consensus for MAIA is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.14.
How accurate are MAIA stock price projections?
Stock price projections, including those for Maia Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.